NO20002044L - Bestemmelse av unormal cellevekst - Google Patents
Bestemmelse av unormal cellevekstInfo
- Publication number
- NO20002044L NO20002044L NO20002044A NO20002044A NO20002044L NO 20002044 L NO20002044 L NO 20002044L NO 20002044 A NO20002044 A NO 20002044A NO 20002044 A NO20002044 A NO 20002044A NO 20002044 L NO20002044 L NO 20002044L
- Authority
- NO
- Norway
- Prior art keywords
- cancerous
- target polypeptides
- determination
- cell growth
- abnormal cell
- Prior art date
Links
- 230000002159 abnormal effect Effects 0.000 title abstract 2
- 230000010261 cell growth Effects 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102100033711 DNA replication licensing factor MCM7 Human genes 0.000 abstract 2
- 101001018431 Homo sapiens DNA replication licensing factor MCM7 Proteins 0.000 abstract 2
- 238000001574 biopsy Methods 0.000 abstract 2
- 210000001519 tissue Anatomy 0.000 abstract 2
- 201000009030 Carcinoma Diseases 0.000 abstract 1
- 208000035484 Cellulite Diseases 0.000 abstract 1
- 102100039606 DNA replication licensing factor MCM3 Human genes 0.000 abstract 1
- 102100021389 DNA replication licensing factor MCM4 Human genes 0.000 abstract 1
- 102100034001 DNA replication licensing factor MCM5 Human genes 0.000 abstract 1
- 102100033720 DNA replication licensing factor MCM6 Human genes 0.000 abstract 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 abstract 1
- 101000583807 Homo sapiens DNA replication licensing factor MCM2 Proteins 0.000 abstract 1
- 101000963174 Homo sapiens DNA replication licensing factor MCM3 Proteins 0.000 abstract 1
- 101000615280 Homo sapiens DNA replication licensing factor MCM4 Proteins 0.000 abstract 1
- 101001017545 Homo sapiens DNA replication licensing factor MCM5 Proteins 0.000 abstract 1
- 101001018484 Homo sapiens DNA replication licensing factor MCM6 Proteins 0.000 abstract 1
- 206010049752 Peau d'orange Diseases 0.000 abstract 1
- 206010039491 Sarcoma Diseases 0.000 abstract 1
- 230000005856 abnormality Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 210000000621 bronchi Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000036232 cellulite Effects 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 210000003238 esophagus Anatomy 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 210000000867 larynx Anatomy 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 210000001165 lymph node Anatomy 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 230000001394 metastastic effect Effects 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 230000037452 priming Effects 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 abstract 1
- 238000012360 testing method Methods 0.000 abstract 1
- 210000003932 urinary bladder Anatomy 0.000 abstract 1
- 210000001635 urinary tract Anatomy 0.000 abstract 1
- 210000002700 urine Anatomy 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57411—Specifically defined cancers of cervix
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Electrotherapy Devices (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Eye Examination Apparatus (AREA)
- Liquid Crystal Substances (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9722217.8A GB9722217D0 (en) | 1997-10-21 | 1997-10-21 | Determination of cellular growth abnormality |
| GBGB9724134.3A GB9724134D0 (en) | 1997-11-14 | 1997-11-14 | Determination of cellular growth abnormality |
| GBGB9804156.9A GB9804156D0 (en) | 1998-02-26 | 1998-02-26 | Determination of cellular growth abnormality |
| GBGB9810560.4A GB9810560D0 (en) | 1998-05-15 | 1998-05-15 | Determination of cellular growth abnormality |
| GBGB9817075.6A GB9817075D0 (en) | 1998-08-05 | 1998-08-05 | Determination of cellular growth abnormality |
| PCT/GB1998/003153 WO1999021014A1 (en) | 1997-10-21 | 1998-10-21 | Determination of cellular growth abnormality |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20002044D0 NO20002044D0 (no) | 2000-04-18 |
| NO20002044L true NO20002044L (no) | 2000-06-07 |
Family
ID=27517431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20002044A NO20002044L (no) | 1997-10-21 | 2000-04-18 | Bestemmelse av unormal cellevekst |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP1025444B1 (pt) |
| JP (2) | JP2000511291A (pt) |
| CN (1) | CN1282422A (pt) |
| AT (1) | ATE290213T1 (pt) |
| AU (1) | AU751754B2 (pt) |
| BR (1) | BR9813127A (pt) |
| CA (1) | CA2305872C (pt) |
| CO (1) | CO5080817A1 (pt) |
| DE (1) | DE69829198T2 (pt) |
| DK (1) | DK1025444T3 (pt) |
| ES (1) | ES2239407T3 (pt) |
| GB (1) | GB2332515B (pt) |
| HU (1) | HUP0004134A2 (pt) |
| IL (1) | IL135602A0 (pt) |
| IS (1) | IS5456A (pt) |
| MA (1) | MA26557A1 (pt) |
| NO (1) | NO20002044L (pt) |
| NZ (1) | NZ503996A (pt) |
| PE (1) | PE20000121A1 (pt) |
| PL (1) | PL340057A1 (pt) |
| PT (1) | PT1025444E (pt) |
| SK (1) | SK5592000A3 (pt) |
| WO (1) | WO1999021014A1 (pt) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6361954B1 (en) | 1996-05-02 | 2002-03-26 | Cold Spring Harbor Laboratory | Methods of immunoassay for human CDC6 |
| GB0018140D0 (en) * | 2000-07-24 | 2000-09-13 | Medical Res Council | Screening for abnormalities |
| DE10063179A1 (de) * | 2000-12-18 | 2002-06-20 | Bayer Ag | Verfahren zur spezifischen Detektion von Tumorzellen und ihren Vorstufen in Gebärmutterhalsabstrichen durch simultane Messung von mindestens zwei verschiedenen molekularen Markern |
| DE10063112A1 (de) | 2000-12-18 | 2002-06-20 | Bayer Ag | Verfahren zur Erhöhung der klinischen Spezifität bei der Detektion von Tumoren und ihren Vorstufen durch simultane Messung von mindestens zwei verschiedenen molekularen Markern |
| EP1373896A2 (en) | 2001-03-12 | 2004-01-02 | MonoGen, Inc. | Cell-based detection and differentiation of disease states |
| EP1369694A1 (en) | 2002-04-09 | 2003-12-10 | MTM Laboratories AG | Method for discrimination of metaplasias from neoplastic or preneoplastic lesions |
| JP2006514823A (ja) * | 2002-08-20 | 2006-05-18 | ミレニアム ファーマスーティカルズ インク | 子宮頸癌の同定、評価、予防および治療を行うための組成物、キットおよび方法 |
| EP1422526A1 (en) | 2002-10-28 | 2004-05-26 | MTM Laboratories AG | Method for improved diagnosis of dysplasias |
| WO2004074301A2 (en) * | 2003-02-14 | 2004-09-02 | Smithkline Beecham Corporation | Differentially expressed nucleic acids that correlate with ksp expression |
| US7361460B2 (en) | 2003-04-11 | 2008-04-22 | Digene Corporation | Approach to molecular diagnosis of human papillomavirus-related diseases |
| US20070122909A1 (en) * | 2003-10-20 | 2007-05-31 | Syssmex Corporation | Method of treating cells |
| EP2293069A3 (en) * | 2004-03-24 | 2011-09-21 | Tripath Imaging, Inc. | Methods and compositions for the detection of cervical disease |
| US7595380B2 (en) * | 2005-04-27 | 2009-09-29 | Tripath Imaging, Inc. | Monoclonal antibodies and methods for their use in the detection of cervical disease |
| GB0518877D0 (en) * | 2005-09-15 | 2005-10-26 | Medical Res Council | Markers and methods |
| US7632498B2 (en) | 2005-12-19 | 2009-12-15 | Tripath Imaging, Inc. | MCM6 and MCM7 monoclonal antibodies and methods for their use in the detection of cervical disease |
| EP2468899B1 (en) | 2006-01-05 | 2015-03-11 | The Ohio State University Research Foundation | MicroRNA-based methods for the diagnosis of stomach cancers |
| AU2007227423B2 (en) | 2006-03-20 | 2013-11-07 | The Ohio State University Research Foundation | MicroRNA fingerprints during human megakaryocytopoiesis |
| DE102006020852A1 (de) | 2006-05-04 | 2007-11-15 | Robert Bosch Gmbh | Gasdruckbehälter für gasbetriebene Kraftfahrzeuge |
| CN103866008B (zh) | 2007-08-03 | 2016-06-29 | 俄亥俄州立大学研究基金会 | 编码ncrna的超保守区域 |
| GB0811567D0 (en) * | 2008-06-24 | 2008-07-30 | Cytosystems Ltd | Assay |
| CN102803511A (zh) | 2009-11-23 | 2012-11-28 | 俄亥俄州立大学 | 用于影响肿瘤细胞生长、迁移和侵袭的材料和方法 |
| GB0921873D0 (en) * | 2009-12-15 | 2010-01-27 | Cytosystems Ltd | Assay |
| AU2011326032B2 (en) | 2010-11-12 | 2016-10-06 | The Ohio State University Research Foundation | Materials and methods related to microRNA-21, mismatch repair, and colorectal cancer |
| BR112013011942A2 (pt) | 2010-11-15 | 2016-11-01 | Univ Michigan | formulação, forma de dosagem de droga para administração transmucosa oral, sistema transmucoso de fornecimento de droga, método de tratamento e profilaxia de uma doença ou distúrbio, método de tratamento, formulação, método para tratamento ou prevenção de carcinoma de célula escamosa de cabeça e pescoço (hnscc), método para quimioprevenção de um câncer oral ou condição pré-cancerosa, método para aumentar a concentração de uma composição de retinida, método de tratamento e profilaxia de uma doença ou condição, método de ratamento de um sujeito apresentando uma condição médica sintomática, método de tratamento de um câncer oral ou condição pré-cancerosa num paciente, método para fazer um sistema de fornecimento de droga bucal, método para aumentar a liberação e permeação de uma composição de retinida. |
| WO2012090479A1 (en) * | 2010-12-28 | 2012-07-05 | Oncotherapy Science, Inc. | Mcm7 as a target gene for cancer therapy and diagnosis |
| AU2012323924A1 (en) | 2011-10-14 | 2014-05-29 | The Ohio State University | Methods and materials related to ovarian cancer |
| CN104619353A (zh) | 2011-12-13 | 2015-05-13 | 俄亥俄州国家创新基金会 | 与miR-21和miR-29a相关的方法和组合物、外切体抑制和癌症转移 |
| CA2860549A1 (en) * | 2012-01-05 | 2013-07-11 | Christophe Cazaux | Signature for the diagnosis of lung cancer aggressiveness and genetic instability |
| AU2013209477B2 (en) | 2012-01-20 | 2016-12-08 | The Ohio State University | Breast cancer biomarker signatures for invasiveness and prognosis |
| US11306364B2 (en) | 2012-02-18 | 2022-04-19 | Duke University | TERT promoter mutations in gliomas and a subset of tumors |
| EP2956556B1 (en) * | 2013-02-18 | 2019-04-10 | Duke University | Tert promoter mutations in gliomas and a subset of tumors |
| GB201412731D0 (en) * | 2014-07-17 | 2014-09-03 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| AU2016261279B2 (en) * | 2015-05-10 | 2020-12-10 | Ventana Medical Systems, Inc. | Compositions and methods for simultaneous inactivation of alkaline phosphatase and peroxidase enzymes during automated multiplex tissue staining assays |
| EP3304082B1 (en) | 2015-06-08 | 2020-05-13 | Arquer Diagnostics Limited | Methods for analysing a urine sample |
| ES2911415T3 (es) | 2015-06-08 | 2022-05-19 | Arquer Diagnostics Ltd | Métodos y kits |
| GB201509907D0 (en) * | 2015-06-08 | 2015-07-22 | Urosens Ltd | Antibodies |
| GB201511196D0 (en) | 2015-06-25 | 2015-08-12 | Cytosystems Ltd | Monoclonal antibodies |
| JP6245299B2 (ja) * | 2016-04-27 | 2017-12-13 | バクスアルタ ゲーエムベーハー | 組換え安定細胞クローン、その産生およびその使用 |
| CN106636343B (zh) * | 2016-11-04 | 2021-03-19 | 深圳大学 | 一种检测口腔癌的标志物及其试剂盒 |
| GB201820867D0 (en) * | 2018-12-20 | 2019-02-06 | Arquer Diagnostics Ltd | Detection method |
| CN115453108A (zh) * | 2019-12-11 | 2022-12-09 | 广东菲鹏生物有限公司 | 用于免疫诊断试剂中固相载体的封闭阶段处理剂及应用和产品 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK144485A (da) * | 1984-03-30 | 1985-10-01 | Syntex Inc | Monoklonale antistoffer |
| US5851821A (en) * | 1996-05-02 | 1998-12-22 | Cold Spring Harbor Laboratory | DNA Replication-regulating genes |
| EP0812594A1 (en) * | 1996-06-13 | 1997-12-17 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Compounds that interfere with DNA replication in rapidly proliferating cells for use in cancer therapy and methods for screening for such compounds |
| US5858683A (en) * | 1996-08-30 | 1999-01-12 | Matritech, Inc. | Methods and compositions for the detection of cervical cancer |
-
1998
- 1998-10-21 CO CO98061237A patent/CO5080817A1/es unknown
- 1998-10-21 IL IL13560298A patent/IL135602A0/xx unknown
- 1998-10-21 AU AU95502/98A patent/AU751754B2/en not_active Expired
- 1998-10-21 BR BR9813127-3A patent/BR9813127A/pt not_active Application Discontinuation
- 1998-10-21 PT PT98949123T patent/PT1025444E/pt unknown
- 1998-10-21 CA CA002305872A patent/CA2305872C/en not_active Expired - Lifetime
- 1998-10-21 PL PL98340057A patent/PL340057A1/xx unknown
- 1998-10-21 MA MA25308A patent/MA26557A1/fr unknown
- 1998-10-21 CN CN98812478A patent/CN1282422A/zh active Pending
- 1998-10-21 JP JP11523482A patent/JP2000511291A/ja active Pending
- 1998-10-21 WO PCT/GB1998/003153 patent/WO1999021014A1/en active IP Right Grant
- 1998-10-21 AT AT98949123T patent/ATE290213T1/de active
- 1998-10-21 PE PE1998000991A patent/PE20000121A1/es not_active Application Discontinuation
- 1998-10-21 SK SK559-2000A patent/SK5592000A3/sk unknown
- 1998-10-21 EP EP98949123A patent/EP1025444B1/en not_active Expired - Lifetime
- 1998-10-21 ES ES98949123T patent/ES2239407T3/es not_active Expired - Lifetime
- 1998-10-21 GB GB9823069A patent/GB2332515B/en not_active Expired - Lifetime
- 1998-10-21 DE DE69829198T patent/DE69829198T2/de not_active Expired - Lifetime
- 1998-10-21 NZ NZ503996A patent/NZ503996A/en not_active IP Right Cessation
- 1998-10-21 DK DK98949123T patent/DK1025444T3/da active
- 1998-10-21 HU HU0004134A patent/HUP0004134A2/hu unknown
-
2000
- 2000-04-17 IS IS5456A patent/IS5456A/is unknown
- 2000-04-18 NO NO20002044A patent/NO20002044L/no not_active Application Discontinuation
-
2003
- 2003-01-15 JP JP2003007249A patent/JP3774196B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ATE290213T1 (de) | 2005-03-15 |
| PL340057A1 (en) | 2001-01-15 |
| NO20002044D0 (no) | 2000-04-18 |
| EP1025444A1 (en) | 2000-08-09 |
| ES2239407T3 (es) | 2005-09-16 |
| AU9550298A (en) | 1999-05-10 |
| IL135602A0 (en) | 2001-05-20 |
| GB2332515A (en) | 1999-06-23 |
| EP1025444B1 (en) | 2005-03-02 |
| BR9813127A (pt) | 2000-08-15 |
| GB9823069D0 (en) | 1998-12-16 |
| IS5456A (is) | 2000-04-17 |
| JP2003240786A (ja) | 2003-08-27 |
| CN1282422A (zh) | 2001-01-31 |
| WO1999021014A1 (en) | 1999-04-29 |
| DK1025444T3 (da) | 2005-06-27 |
| MA26557A1 (fr) | 2004-12-20 |
| DE69829198T2 (de) | 2006-01-12 |
| HUP0004134A2 (en) | 2001-03-28 |
| CO5080817A1 (es) | 2001-09-25 |
| PE20000121A1 (es) | 2000-02-17 |
| GB2332515B (en) | 1999-12-15 |
| DE69829198D1 (de) | 2005-04-07 |
| JP2000511291A (ja) | 2000-08-29 |
| CA2305872A1 (en) | 1999-04-29 |
| CA2305872C (en) | 2008-02-19 |
| AU751754B2 (en) | 2002-08-29 |
| PT1025444E (pt) | 2005-07-29 |
| JP3774196B2 (ja) | 2006-05-10 |
| NZ503996A (en) | 2002-04-26 |
| SK5592000A3 (en) | 2000-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20002044L (no) | Bestemmelse av unormal cellevekst | |
| Canaani et al. | Altered transcription of an oncogene in chronic myeloid leukaemia | |
| Bonnier et al. | Age as a prognostic factor in breast cancer: relationship to pathologic and biologic features | |
| Henson et al. | Carcinoma of the extrahepatic bile ducts. Histologic types, stage of disease, grade, and survival rates | |
| Gimenez‐Conti et al. | p53, Rb, and cyclin D1 expression in human oral verrucous carcinomas | |
| Lee | Mucins in Barrett’s esophagus: a histochemical study | |
| De Maria et al. | Survivin gene-expression and splicing isoforms in oral squamous cell carcinoma | |
| Retz et al. | Differential mucin MUC7 gene expression in invasive bladder carcinoma in contrast to uniform MUC1 and MUC2 gene expression in both normal urothelium and bladder carcinoma | |
| Inoue et al. | Bcl-2 overexpression enhances in vitro sensitivity against docetaxel in non-small cell lung cancer | |
| Huang et al. | LAMA4, highly expressed in human hepatocellular carcinoma from Chinese patients, is a novel marker of tumor invasion and metastasis | |
| Rumilla et al. | Galectin-4 expression in carcinoid tumors | |
| Salama et al. | Urinary tumor markers could predict survival in bladder carcinoma | |
| AR014382A1 (es) | Determinacion de anormalidad en el crecimiento celular | |
| Geng et al. | Expression of telomerase hTERT in human non-small cell lung cancer and its correlation with c-myc gene | |
| Matsuyama et al. | Gallbladder cancers rarely overexpress HER-2/neu, demonstrated by Hercep test | |
| TH41035B (th) | การกำหนดของความผิดปกติในการเจริญเติบโตของเซลล์ | |
| TH41035A (th) | การกำหนดของความผิดปกติในการเจริญเติบโตของเซลล์ | |
| Zacho et al. | Surgical treatment of gastric malignancies: a twenty-year series comprising mainly far advanced and high-seated tumors. | |
| Tricarico et al. | Quantitative RT-PCR assay for VEGF mRNA in human tumors of the kidney | |
| Konaktchieva et al. | Intraductal papillary mucinous neoplasm of the pancreas: need for a tailored approach to a rare entity | |
| Budu et al. | Malignant melanoma of the left nasal fossa-case report | |
| Gupta et al. | Tissue isoantigens A, B, and H in carcinoma of the cervix uteri: their clinical significance | |
| Sakayama et al. | Proliferative activity of osteosarcoma cells: comparison of osteoblastic and nonosteoblastic regions | |
| Salama et al. | Urinary tumor marker in bladder carcinoma in Upper Egypt, correlations with different clinicopathological features | |
| Verschraegen et al. | Clinical presentation and natural history of mesothelioma: abdominal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |